Published in EMBO J on September 03, 2001
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer (2009) 5.02
A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell (2011) 3.69
The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest (2002) 3.23
Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol Cell (2007) 1.87
Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol (2002) 1.75
Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med (2014) 1.62
Beta-catenin regulation during the cell cycle: implications in G2/M and apoptosis. Mol Biol Cell (2003) 1.62
Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev (2002) 1.50
Extracellular matrix alterations in conventional renal cell carcinomas by tissue microarray profiling influenced by the persistent, long-term, low-dose ionizing radiation exposure in humans. Virchows Arch (2006) 1.50
Wnt signalling and the control of cellular metabolism. Biochem J (2010) 1.42
Beta-catenin expression results in p53-independent DNA damage and oncogene-induced senescence in prelymphomagenic thymocytes in vivo. Mol Cell Biol (2007) 1.21
Wnt/β-catenin signaling induces the aging of mesenchymal stem cells through the DNA damage response and the p53/p21 pathway. PLoS One (2011) 1.19
Complete deletion of Apc results in severe polyposis in mice. Oncogene (2009) 1.16
Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug. Am J Pathol (2009) 1.13
Kindlin 2 forms a transcriptional complex with β-catenin and TCF4 to enhance Wnt signalling. EMBO Rep (2012) 1.12
Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc) (2007) 1.11
The Regulation of Multiple p53 Stress Responses is Mediated through MDM2. Genes Cancer (2012) 1.06
Pak4 induces premature senescence via a pathway requiring p16INK4/p19ARF and mitogen-activated protein kinase signaling. Mol Cell Biol (2005) 1.05
Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN. PLoS One (2011) 1.04
Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. BMC Immunol (2006) 1.01
Normal p53 function in primary cells deficient for Siah genes. Mol Cell Biol (2002) 0.99
Early embryonic death in mice lacking the beta-catenin-binding protein Duplin. Mol Cell Biol (2004) 0.98
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood (2008) 0.97
Adenomatous polyposis coli and hypoxia-inducible factor-1{alpha} have an antagonistic connection. Mol Biol Cell (2010) 0.97
Novel ARF/p53-independent senescence pathways in cancer repression. J Mol Med (Berl) (2011) 0.95
Beta-catenin simultaneously induces activation of the p53-p21WAF1 pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells. Am J Pathol (2004) 0.91
Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. Proc Natl Acad Sci U S A (2008) 0.90
MicroRNA-29 induces cellular senescence in aging muscle through multiple signaling pathways. Aging (Albany NY) (2014) 0.89
Enhanced endothelial cell senescence by lithium-induced matrix metalloproteinase-1 expression. J Biol Chem (2009) 0.86
Immunohistochemical investigation of cell cycle and apoptosis regulators (survivin, β-catenin, p53, caspase 3) in canine appendicular osteosarcoma. BMC Vet Res (2012) 0.85
Physical and functional interaction between ribosomal protein L11 and the tumor suppressor ARF. J Biol Chem (2012) 0.85
Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med (2007) 0.84
Molecular basis for the tissue specificity of β-catenin oncogenesis. Oncogene (2012) 0.83
The THO ribonucleoprotein complex is required for stem cell homeostasis in the adult mouse small intestine. Mol Cell Biol (2013) 0.83
High levels of β-catenin promote IFNγ-induced apoptosis in hepatocellular carcinoma cells. Oncol Lett (2012) 0.83
P53 and beta-catenin activity during estrogen treatment of osteoblasts. Cancer Cell Int (2005) 0.82
Upregulation of p16(INK4A) and Bax in p53 wild/p53-overexpressing crypts in ulcerative colitis-associated tumours. Br J Cancer (2004) 0.80
The balance of TCF7L2 variants with differential activities in Wnt-signaling is regulated by lithium in a GSK3beta-independent manner. Biochem Biophys Res Commun (2010) 0.80
β-Catenin C-terminal signals suppress p53 and are essential for artery formation. Nat Commun (2016) 0.80
Pygo2 regulates β-catenin-induced activation of hair follicle stem/progenitor cells and skin hyperplasia. Proc Natl Acad Sci U S A (2014) 0.79
Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis. Nat Commun (2015) 0.78
Immunohistochemical study of β-catenin and functionally related molecular markers in tongue squamous cell carcinoma and its correlation with cellular proliferation. Oncol Lett (2010) 0.77
Prognostic significance of survivin, β-catenin and p53 expression in urothelial carcinoma. Bosn J Basic Med Sci (2015) 0.76
Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis. Transl Cancer Res (2016) 0.76
Increased expression of prothymosin-α, independently or combined with TP53, correlates with poor prognosis in colorectal cancer. Int J Clin Exp Pathol (2014) 0.75
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
Cancer cell cycles. Science (1996) 21.29
Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (1999) 20.34
Wnt signaling and cancer. Genes Dev (2000) 18.53
Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 16.60
Functional interaction of beta-catenin with the transcription factor LEF-1. Nature (1996) 15.88
beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J (1997) 12.97
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell (1997) 12.41
Linking colorectal cancer to Wnt signaling. Cell (2000) 11.58
The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A (1999) 10.75
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev (1998) 9.03
Signaling to p53: breaking the MDM2-p53 circuit. Cell (1998) 8.63
Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science (1998) 8.27
Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell (1997) 8.23
De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Cell (1998) 7.95
Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J (1998) 7.59
The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev (1998) 7.46
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell (1995) 7.34
Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. Science (2000) 7.25
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev (1999) 6.87
The p53 pathway. J Pathol (1999) 6.79
From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet (1993) 6.77
The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev (1999) 6.56
Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell (1990) 6.37
The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J (1998) 6.08
Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol (1999) 5.78
p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A (1990) 5.43
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet (2000) 5.26
Tumor surveillance via the ARF-p53 pathway. Genes Dev (1998) 5.11
p19ARF links the tumour suppressor p53 to Ras. Nature (1998) 4.89
p14ARF links the tumour suppressors RB and p53. Nature (1998) 4.78
Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J (1999) 4.69
E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev (1998) 4.60
Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ (1998) 4.38
Gain of function mutations in p53. Nat Genet (1993) 4.19
The ARF/p53 pathway. Curr Opin Genet Dev (2000) 4.13
The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol (1999) 4.06
A common human skin tumour is caused by activating mutations in beta-catenin. Nat Genet (1999) 3.93
P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A (1999) 3.78
The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J (2000) 3.77
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76
Beta-catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev (1998) 3.65
LEF-1, a nuclear factor coordinating signaling inputs from wingless and decapentaplegic. Cell (1997) 3.63
The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev (1999) 3.50
p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol (2000) 3.15
Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol (2000) 3.12
Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci U S A (1995) 3.06
Regulation of the p53 tumor suppressor protein. J Biol Chem (1999) 2.94
Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell (1999) 2.93
The APC tumour suppressor has a nuclear export function. Nature (2000) 2.82
p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev (2000) 2.74
WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev (2000) 2.67
The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol (1998) 2.53
Differential nuclear translocation and transactivation potential of beta-catenin and plakoglobin. J Cell Biol (1998) 2.38
Differential molecular interactions of beta-catenin and plakoglobin in adhesion, signaling and cancer. Curr Opin Cell Biol (1998) 2.34
Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol (2000) 2.34
Plakoglobin and beta-catenin: protein interactions, regulation and biological roles. J Cell Sci (2000) 2.32
Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell (2000) 2.30
Identification of a cryptic nucleolar-localization signal in MDM2. Nat Cell Biol (2000) 2.02
Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res (2000) 1.95
Differential mechanisms of LEF/TCF family-dependent transcriptional activation by beta-catenin and plakoglobin. Mol Cell Biol (2000) 1.93
Expression cloning of oncogenes by retroviral transfer of cDNA libraries. Mol Cell Biol (1995) 1.89
Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol Cell Biol (1998) 1.82
p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. Proc Natl Acad Sci U S A (1998) 1.73
Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci U S A (1999) 1.65
Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J (1999) 1.63
Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci U S A (2000) 1.54
p53 mutations: gains or losses? J Cell Biochem (1991) 1.33
The loss of mdm2 induces p53-mediated apoptosis. Oncogene (2000) 1.31
Regulation and activation of p53 and its family members. Cell Death Differ (1999) 1.27
Differential interaction of plakoglobin and beta-catenin with the ubiquitin-proteasome system. Oncogene (2000) 1.25
Regulation and functions of the glycogen synthase kinase-3 subfamily. Semin Cancer Biol (1994) 1.25
Activation of p53 by oncogenes. Endocr Relat Cancer (1999) 1.24
APC: the plot thickens. Curr Opin Genet Dev (1999) 1.11
Lithium inhibits cell cycle progression and induces stabilization of p53 in bovine aortic endothelial cells. J Biol Chem (2001) 1.04
Wingless signaling: the inconvenient complexities of life. Curr Biol (1998) 0.87
Armadillo takes the APC shuttle. Nat Cell Biol (2000) 0.78
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A (1999) 10.75
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (1991) 9.21
mdm2 expression is induced by wild type p53 activity. EMBO J (1993) 8.01
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (1985) 6.86
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol (1988) 6.44
Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell (1990) 6.37
Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A (1989) 5.40
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev (2001) 4.06
Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci U S A (2000) 3.74
The outer boundary of the cytoskeleton: a lamina derived from plasma membrane proteins. Cell (1979) 3.66
Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (1999) 3.50
Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A (1991) 3.45
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev (1995) 3.40
Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol (1983) 3.39
Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol (1992) 3.37
p53 in growth control and neoplasia. Biochim Biophys Acta (1996) 3.19
Mechanisms of regulating tubulin synthesis in cultured mammalian cells. Cell (1979) 3.19
Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J (1985) 3.18
p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol (1985) 3.13
Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene (1993) 3.08
A single gene and a pseudogene for the cellular tumour antigen p53. Nature (1984) 2.98
Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature (1986) 2.94
Analysis of the gene coding for the murine cellular tumour antigen p53. EMBO J (1984) 2.94
Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem (2001) 2.93
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 2.91
Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev (1994) 2.88
Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A (1999) 2.87
p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ (2009) 2.80
Protein synthesis requires cell-surface contact while nuclear events respond to cell shape in anchorage-dependent fibroblasts. Cell (1980) 2.80
Differential affinities of simian virus 40 large tumor antigen for DNA. Proc Natl Acad Sci U S A (1980) 2.75
Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol (1990) 2.73
Overproduction of p53 antigen makes established cells highly tumorigenic. Nature (1985) 2.72
Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene (1988) 2.71
Non-visualization of the cavum septi pellucidi is not synonymous with agenesis of the corpus callosum. Ultrasound Obstet Gynecol (2012) 2.65
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J (1999) 2.64
Localization of gene for human p53 tumour antigen to band 17p13. Nature (1986) 2.56
Inhibition of beta-catenin-mediated transactivation by cadherin derivatives. Proc Natl Acad Sci U S A (1998) 2.55
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene (1999) 2.43
p120 catenin affects cell motility via modulation of activity of Rho-family GTPases: a link between cell-cell contact formation and regulation of cell locomotion. J Cell Sci (2001) 2.40
Differential nuclear translocation and transactivation potential of beta-catenin and plakoglobin. J Cell Biol (1998) 2.38
Plakoglobin and beta-catenin: protein interactions, regulation and biological roles. J Cell Sci (2000) 2.32
Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell (2000) 2.30
p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol (1993) 2.27
TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ (2005) 2.25
A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res (1995) 2.23
Different tumor-derived p53 mutants exhibit distinct biological activities. Science (1990) 2.20
The control of mRNA production, translation and turnover in suspended and reattached anchorage-dependent fibroblasts. Cell (1978) 2.19
The 5' region of the p53 gene: evolutionary conservation and evidence for a negative regulatory element. EMBO J (1985) 2.17
Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J (1996) 2.12
Properties of permissive monkey cells transformed by UV-irradiated simian virus 40. J Virol (1977) 2.03
MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol (1999) 2.00
A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol (1996) 1.98
Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature (1996) 1.98
Oligomerization of oncoprotein p53. J Virol (1988) 1.98
Differential mechanisms of LEF/TCF family-dependent transcriptional activation by beta-catenin and plakoglobin. Mol Cell Biol (2000) 1.93
Modulation of bacterial entry into epithelial cells by association between vinculin and the Shigella IpaA invasin. EMBO J (1997) 1.90
Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA. J Cell Biol (1992) 1.89
Regulation of actin mRNA levels and translation responds to changes in cell configuration. Mol Cell Biol (1983) 1.86
SV40 large tumor antigen can regulate some cellular transcripts in a positive fashion. Cell (1982) 1.85
Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J (1996) 1.82
Targeted disruption of vinculin genes in F9 and embryonic stem cells changes cell morphology, adhesion, and locomotion. Proc Natl Acad Sci U S A (1995) 1.82
Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol Cell Biol (1982) 1.82
Transcription regulation by mutant p53. Oncogene (2007) 1.78
The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem (2000) 1.77
Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes. EMBO J (1993) 1.77
Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene (1993) 1.77
Caldesmon inhibits nonmuscle cell contractility and interferes with the formation of focal adhesions. Mol Biol Cell (1999) 1.74
Different forms of simian virus 40 large tumor antigen varying in their affinities for DNA. J Virol (1982) 1.72
Suppression of tumorigenicity in simian virus 40-transformed 3T3 cells transfected with alpha-actinin cDNA. Proc Natl Acad Sci U S A (1993) 1.69
Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene (2000) 1.67
Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. Proc Natl Acad Sci U S A (1983) 1.65
Physical and functional interaction between p53 and the Werner's syndrome protein. J Biol Chem (1999) 1.64
The structural relationships between 54,000-molecular-weight cellular tumor antigens detected in viral- and nonviral-transformed cells. Virology (1981) 1.64
Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J (1994) 1.64
Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J (1999) 1.63
Suppression of vinculin expression by antisense transfection confers changes in cell morphology, motility, and anchorage-dependent growth of 3T3 cells. J Cell Biol (1993) 1.61
Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol Cell Biol (1991) 1.61
Down-regulation of beta-catenin by activated p53. Mol Cell Biol (2001) 1.60
Regulation of beta-catenin levels and localization by overexpression of plakoglobin and inhibition of the ubiquitin-proteasome system. J Cell Biol (1997) 1.59
Overexpression of vinculin suppresses cell motility in BALB/c 3T3 cells. Cell Motil Cytoskeleton (1992) 1.57
Differential control of cytokeratins and vimentin synthesis by cell-cell contact and cell spreading in cultured epithelial cells. J Cell Biol (1984) 1.57
Ketamine enhances local anesthetic and analgesic effects of bupivacaine by peripheral mechanism: a study in postoperative patients. Neurosci Lett (1996) 1.56
Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene (1999) 1.56
Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression. Mol Cell Biol (1993) 1.56
Analysis of recombinant DNA clones specific for the murine p53 cellular tumor antigen. EMBO J (1983) 1.55
The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol Cell Biol (1998) 1.53
Inhibition of cell growth mediated by plasmids encoding p53 anti-sense. Oncogene (1987) 1.52
Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J Biol Chem (2000) 1.51